# Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

> **NCT03162055** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 1119 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease COPD

## Interventions

- **DRUG:** Glycopyrronium/Formoterol Fumarate
- **DRUG:** umeclidinium/vilanterol

## Key facts

- **NCT ID:** NCT03162055
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-25
- **Primary completion:** 2018-05-04
- **Final completion:** 2018-05-04
- **Target enrollment:** 1119 (ACTUAL)
- **Last updated:** 2019-05-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03162055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03162055, "Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03162055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*